- Amgen (NASDAQ:AMGN) Q3 results:
- Revenues: $6,423M (+12.0%); product sales: $6,104M (+11.7%).
- Key product sales: Enbrel: $1,325M (-3.0%); Prolia: $701M (+11.3%); Neulasta: $555M (-21.9%); Otezla: $538M; Xgeva: $481M (+1.1%); Aranesp: $384M (-15.0%).
- Newer products: Repatha: $205M (+22.0%); Parsabiv:$183M(+16.6%); Aimovig: $105M (+59.1%); Evenity: $59M.
- Net income: $2,021M (+2.7%); non-GAAP net income: $2,572M (+16.7%); EPS: $3.43 (+4.9%); non-GAAP EPS: $4.37 (+19.4%).
- Cash flow ops: $3.4B (flat).
- 2020 guidance: Revenues: $25.1B - 25.5B from $25.0B - 25.6B; EPS: $11.53 - 11.93 from $10.73 - 11.43; non-GAAP EPS: $15.80 - 16.15 from $15.10 - 15.75.
- https://seekingalpha.com/news/3627680-amgen-q3-product-sales-up-12-non-gaap-earnings-up-17
Wednesday, October 28, 2020
Amgen Q3 product sales up 12%, non-GAAP earnings up 17%
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.